AstraZeneca Reports Strong Q1-Q3 2019 Results: China Revenue Reaches $3.69 Billion, Up 37% YoY

Source:PharmaCube InfoVernacular Chinese

On October 24, AstraZeneca announced its financial results for the first three quarters of 2019, with product sales revenue reaching $17.315 billion, a year-on-year increase of 17%. Among them, the product sales revenue in the third quarter was $6.132 billion, a year-on-year increase of 18%.

In the first three quarters, AstraZeneca’s oncology portfolio grew by 54%, reaching $6.393 billion; sales revenue from the new CVRM portfolio (Brilinta, Lokelma, and roxadustat) increased by 14%, amounting to $3.207 billion; and respiratory product sales revenue rose by 13%, totaling $3.854 billion.

Revenue in China reached $3.691 billion, a year-on-year increase of 37%. Of this, oncology sales amounted to $1.023 billion, up 67% year on year, while the new CVRM portfolio generated $359 million in sales, representing an 88% year-on-year growth.

In the first three quarters, AstraZeneca’s oncology portfolio grew by 54%, reaching $6.393 billion; sales revenue from its new Cardiovascular, Renal and Metabolism (CVRM) portfolio increased by 14%, amounting to $3.207 billion; and respiratory product sales revenue rose by 13%, totaling $3.854 billion.

Tagrisso’s sales in the first three quarters amounted to $2.305 billion, representing an 86% year-on-year increase. Among this, sales in emerging markets grew by 120%, reaching $553 million, primarily driven by Tagrisso’s inclusion in China’s National Reimbursement Drug List and its approval for first-line treatment of lung cancer. Lynparza’s sales in emerging markets surged by 227%, mainly propelled by its approval in China for ovarian cancer.

In the fourth quarter, AstraZeneca expects Imfinzi (non-small cell lung cancer), Lynparza (ovarian cancer), and PT010 (COPD) to be approved in China. Symbicort (mild asthma) is expected to have its sNDA submitted in China.

AstraZeneca’s Core Drug Sales in the First Three Quarters of 2019 (USD billion)